September 15th 2025
New research highlights the effectiveness of early psychosis intervention programs, emphasizing low caseloads and clozapine access to reduce relapse rates.
Emraclidine for Schizophrenia Fails to Meet Primary Endpoints in Phase 2 EMPOWER Trials
November 11th 2024Emraclidine once-daily, oral monotherapy treatment for adults with schizophrenia experiencing acute psychotic symptoms, failed to meet the primary endpoints in the 2 phase 2 EMPOWER trials.
Read More
TEV-'749: An Option to Serve an Important Treatment Gap for Patients With Schizophrenia
October 14th 2024Learn more about the new positive efficacy, safety, tolerability data from the phase 3 SOLARIS trial, which were presented at the 37th Annual European College of Neuropsychopharmacology Congress.
Read More